VITRAFY LIFE SCIENCES LIMITED (VFY)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

VFY - VITRAFY LIFE SCIENCES LIMITED

FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: N/A
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.80

07 May
2025

-0.090

OPEN

$1.85

-4.76%

HIGH

$1.85

23,025

LOW

$1.80

TARGET
$2.15 19.4% upside
FNARENA'S MARKET CONSENSUS FORECASTS
VFY: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 0.5 - 39.0 xxx
DPS (cps) xxx 0.2 0.0 xxx
EPS Growth xxx 15.4% N/A xxx
DPS Growth xxx 0.0% N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx 44.4% N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.11

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

10/02/2025

1

Speculative Buy

$2.30

27.78%

Ord Minnett observes 1H25 results from Vitrafy Life Sciences met expectations post the company's 2Q25 and IPO details in November 2024.

The broker believes the company will announce more commercialisations in 2025, with updates from the SSI study in March and the US/AUS phase 1 due for completion in 3Q 2025.

With an estimated total addressable market of over US$94bn across bio-banks, cell cryopreservation, and animal breeding/aquaculture, which is expected to double by FY30, Ord Minnett remains upbeat on the company's outlook.

Speculative Buy retained with a target price of $2.30, down from $2.45.

FORECAST
Ord Minnett forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -51.30 cents.
Ord Minnett forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -18.70 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

VFY STOCK CHART

FNArena News on VFY

1
FNArena Corporate Results Monitor – 07-02-2025

Feb 07 2025 - Australia